Atorvastatin warnings and precautions: Difference between revisions

Jump to navigation Jump to search
mNo edit summary
(Redirected page to Atorvastatin#Warnings)
 
(10 intermediate revisions by 2 users not shown)
Line 1: Line 1:
__NOTOC__
#REDIRECT [[Atorvastatin#Warnings]]
{{Atorvastatin}}
{{CMG}} ; {{AE}} , {{PB}}
 
 
Skeletal muscle effects (e.g., [[myopathy]] and [[rhabdomyolysis]]): Risks increase when higher doses are used concomitantly with [[cyclosporine]] and strong [[CYP3A4]] inhibitors (e.g., [[clarithromycin]], [[itraconazole]], HIV [[protease inhibitor]]s). Predisposing factors include advanced age (> 65), uncontrolled [[hypothyroidism]], and renal impairment.
 
Rare cases of [[rhabdomyolysis]] with [[acute renal failure]] secondary to [[myoglobinuria]] have been reported. Advise patients to promptly report to their physician unexplained and/or persistent muscle pain, tenderness, or weakness. atorvastatin therapy should be discontinued if [[myopathy]] is diagnosed or suspected.
 
Liver enzyme abnormalities: Persistent elevations in hepatic [[transaminase]]s can occur. Check liver enzyme tests before initiating therapy and as clinically indicated thereafter.
 
A higher incidence of [[hemorrhagic stroke]] was seen in patients without [[CHD]] but with [[stroke]] or [[TIA]] within the previous 6 months in the atorvastatin 80 mg group vs placebo.<ref name="dailymed.nlm.nih.gov">{{Cite web  | last =  | first =  | title = LIPITOR (ATORVASTATIN CALCIUM) TABLET, FILM COATED [PARKE-DAVIS DIV OF PFIZER INC] | url = http://dailymed.nlm.nih.gov/dailymed/lookup.cfm?setid=c6e131fe-e7df-4876-83f7-9156fc4e8228#nlm34089-3 | publisher =  | date =  | accessdate = }}</ref>
 
 
==References==
{{Reflist}}
 
{{FDA}}
 
[[Category:Cardiovascular Drugs]]
[[Category:Drugs]]

Latest revision as of 14:43, 22 July 2014